newsfilter
← Earnings
Earnings Releases·

ImageneBio — Third Quarter 2026 Earnings Summary

  • Net loss for Q3 2026 narrowed to $15.6 million ($0.91 per share) from $24.8 million ($2.91 per share) in the prior year period, driven by a $3.9 million reduction in R&D and $5.0 million reduction in G&A expenses.
  • Cash, cash equivalents, and marketable securities totaled $126.6 million as of September 30, 2026, with management projecting these resources will fund operations through Q1 2028.
  • Clinical development remains on track: Phase 2b ADAPTIVE trial data for olevaprubart in atopic dermatitis is expected in Q4 2027, while a Phase 2 study in alopecia areata is scheduled to initiate by year-end 2026.
  • Share count increased to 12.46 million from 10.65 million as of December 31, 2025, and accumulated deficit grew to $(266.5) million, while no license revenue was recorded in the current quarter.
Company
IMAGENEBIO INC
Sector
Healthcare
Industry
Biotechnology